FIGO2018ⅢC期宫颈癌的预后及治疗策略  

Prognosis and Treatment Strategies of FIGO 2018 StageⅢC Cervical Cancer

作　　者：马杏 刘畅[2] MA Xing;LIU Chang(The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Obstetrics and Gynecology,the First Hospital of Lanzhou University,Gansu Provincial Clinical Research Center for Gynecological Oncology,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院妇产科甘肃省妇科肿瘤临床研究中心,兰州730000

出　　处：《协和医学杂志》2024年第6期1253-1260,共8页Medical Journal of Peking Union Medical College Hospital

摘　　要：肿瘤分期和淋巴结受累是局部晚期宫颈癌最重要的预后因素。对于宫颈癌,妇科肿瘤医师普遍应用国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)标准。然而目前FIGO 2018分期标准中,ⅢC期仅基于转移淋巴结的解剖位置,并未考虑局部肿瘤因素及其他淋巴状态参数,一定程度上限制了其预后意义。本文旨在总结ⅢC期宫颈癌局部肿瘤因素及不同淋巴状态参数对预后的影响以及治疗选择。Tumor stage and lymph node involvement are the most important prognostic factors for patients with locally advanced cervical cancer.For cervical cancer,gynecologic oncologists generally apply the criteria of the International Federation of Gynecology and Obstetrics(FIGO).However,in the current FIGO 2018 staging system,stageⅢC is based only on the anatomical location of metastatic lymph nodes,without considering local tumor factors and other lymphatic status parameters,which limits its prognostic significance to a certain extent.The aim of this article is to summarize the influence of local tumor factors and different lym-phatic status parameters on prognosis and treatment options for stageⅢC cervical cancer.

关 键 词：宫颈癌 国际妇产科联盟 ⅢC期 肿瘤异质性 治疗 预后 

分 类 号：R737.33[医药卫生—肿瘤] R-17[医药卫生—临床医学]